Clinical Research Directory
Browse clinical research sites, groups, and studies.
Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure
Sponsor: University of Michigan
Summary
The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron emission tomography-based amyloid and tau burden and associated risk of conversion to Dementia-Alzheimer's Type. Healthcare access will be explored as potential barrier to or facilitator of behavior change.
Official title: Behavioral Change Following Culturally Informed Biomarker Disclosure in Alzheimer's Disease
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-02-20
Completion Date
2026-05
Last Updated
2026-01-08
Healthy Volunteers
No
Interventions
Diagnostic Disclosure Protocol
Personalized disclosure on cognitive test results and research diagnosis, plus post-disclosure dementia risk reduction counseling.
Biomarker Disclosure Protocol
Participants receive information about their cognitive test results and research diagnosis just like in the diagnostic disclosure protocol. In addition, participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging. PET is a type of imaging biomarker (Aß-PET and tau PET) for clinical diagnosis of Alzheimer's disease. These actions are followed by post-disclosure dementia risk reduction counseling.
Locations (1)
The University of Michigan
Ann Arbor, Michigan, United States